NCT04556916Toboroz
Early Detection of Prostate Cancer
Early Detection of Prostate Cancer by Liquid Biopsy
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 22.
Rövid összefoglaló (regiszter, angolul)
This study is the early detection of prostate cancer by analysing circulating bloodbased biomarkers. Based on our latest developments, we primarily aim to assess the validity of CTCs (circulating tumour cells) and tumour cell products circulating in blood (DNA, exosomes) for early PCa (Prostate cancer) detection. In the first discovery period, the investigators will assess which Liquid biopsy marker will provide the best discrimination between the patients with histologically proven PCa and age-matched noncancer controls. Further subset analysis with special emphasis on the identification of high risk PCa patients with aggressive tumours as defined by a Gleason score ("gold standard") of 8 or higher (ISUP 4 and higher), will be performed. The resulting biomarker candidates will then be further explored in the subsequent training and validation study (years 2 and 3) in order to obtain the single blood test or combination of tests with the highest sensitivity and specificity for detection of early PCa and/or high-risk PCa. The investigators will also compare these new biomarkers with recently FDA cleared CE-IVD assays for early detection of prostate cancer, based on classic peripheral tumour markers, such as Prostate Health Index (PHI) and PCA3. Follow up evaluations will be initiated to assess the prognostic relevance of the candidate biomarkers determined in this project. Here, the investigators will set up the data management system including all relevant information on the tissues collected and the results of the analyses as well as the clinical data of the patients investigated in this study.
- Állapot (regiszter)
- Toboroz
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 320 (tervezett)
- Első benyújtás
- 2020. jún. 23.
- Kezdés
- 2021. febr. 19.
- Elsődleges befejezés
- 2023. nov. 15.
- Fő szponzor
- University Hospital, Montpellier
- Betegségek
- Prosztatarák
- NCT-szám
- NCT04556916
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 320
- 2021. febr. 19. és az elsődleges befejezés (2023. nov. 15.) között
- 4 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- Subject with histologically confirmed prostate cancer
- Subject with a verified viral infection (HIV or Hepatitis)
- Subject with other cancer diagnosed
- Urinary infection ≤ 2 months
- Subject with histologically confirmed prostate cancer
- Subject with a verified viral infection (HIV or Hepatitis)
- Subject with other cancer diagnosed
- Urinary infection ≤ 2 months
Egyéb
- Subject under Finasteride treatment
- Subject under hormonal treatment (analogs, antagonists, androgenics)
- Subject unable to sign consent
- Planned longer stay outside the region that prevents compliance with the visit plan
- Subject deprived of liberty, protected adults or vulnerable persons
- Subject excluding health insurance registration
- Subject refusing to perform prostate biopsy
- Subject who are in a dependency or employment with the sponsor or the investigator
- Subject under Finasteride treatment
- Subject unable to sign consent
- Planned longer stay outside the region that prevents compliance with the visit plan
- Subject deprived of liberty, protected adults or vulnerable persons
- Subject excluding health insurance registration
Kiket keres a vizsgálat
- Men over 40 being suspicious of prostate cancer
- Subject with PSA ≥ 4 and designated for biopsy
- Subjects must be able to attend all scheduled visits and to comply with all trial procedures
- mpMRI done before prostate biopsy
- Subject must be covered by public health insurance
- Signed informed consent form
- Men over 40 with no suspicion of prostate cancer
- Subject with PSA < 2.5 and normal digital rectal examination
- Subject must be covered by public health insurance
- Signed informed consent form
Életkor a regiszterben: 40 év – - · Nem: csak férfiak · Egészséges önkénteseket nem fogad
Helyszínek (4)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| CHU Montpellier - Département d'urologie et transplantation rénale | Montpellier | Franciaország | Toboroz |
| CHU Montpellier - Laboratoire des Cellules Circulantes Rares Humaines | Montpellier | Franciaország | Fut, nem toboroz |
| Clinique Beau Soleil - Service d'urologie | Montpellier | Franciaország | Toboroz |
| CHU de Nîmes - Service Urologie Andrologie Sexologie | Nîmes | Franciaország | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.